SS Innovations International Inc. (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the company's SSi Mantra 3.0 surgical robotic system. This development represents a significant milestone in the adoption of robotic-assisted cardiac procedures in South Asia and underscores the growing global reach of SS Innovations' technology.
The program commenced with a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This initial procedure demonstrates the feasibility and potential of robotic systems in complex cardiac surgeries, which traditionally require large incisions and lengthy recovery periods. By enabling minimally invasive techniques, robotic systems like the SSi Mantra can reduce patient trauma, shorten hospital stays, and improve overall outcomes.
According to a recent company video describing the program's early activity, Kings Hospital has already completed more than 25 robotic procedures in just three weeks. This rapid adoption highlights the enthusiasm and trust that medical professionals in Sri Lanka have placed in the technology. It also signals a broader trend: hospitals in emerging markets are increasingly investing in advanced surgical robotics to enhance their clinical capabilities and attract patients seeking cutting-edge care.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These figures indicate not only growing sales but also rising utilization of the installed base, as more surgeons become proficient with the system and expand its applications. The expansion into Sri Lanka is part of this upward trajectory, potentially opening doors to neighboring countries and further establishing SS Innovations as a key player in the global surgical robotics market.
The next major corporate milestone for SS Innovations is regulatory expansion, with the company pursuing U.S. Food and Drug Administration (FDA) clearance and European CE marking for the SSi Mantra system. Achieving these certifications would allow the company to enter two of the largest and most lucrative healthcare markets in the world. It would also provide a significant competitive advantage, as regulatory approval from the FDA and CE mark are widely recognized as benchmarks for safety and efficacy. For investors, this represents a critical catalyst that could drive substantial revenue growth and stock appreciation.
For more information, visit the company's newsroom at https://ibn.fm/SSII. Additionally, details about TechMediaWire, the communications platform that distributes company news, can be found at https://www.TechMediaWire.com.
